<table id="t300" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Clinically significant drug interactions with BUPRENEX.
</caption>
<col align="left" width="25.350%"></col>
<col align="left" width="74.650%"></col>
<tbody>
<tr>
<td align="left" colspan="2" stylecode="Toprule Botrule Lrule Rrule" valign="top">
<content stylecode="bold">Benzodiazepines and Other Central Nervous System (CNS) Depressants</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Due to additive pharmacologic effect, the concomitant use of benzodiazepines or other CNS depressants, including alcohol, can increase the risk of hypotension, respiratory depression, profound sedation, coma, and death.
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients closely for signs of respiratory depression and sedation <content stylecode="italics">[see <linkhtml href="#s20">WARNINGS</linkhtml>].</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Examples:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Benzodiazepines and other sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, and other opioids, alcohol.
</td>
</tr>
<tr>
<td align="left" colspan="2" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="bold">Inhibitors of CYP3A4</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">The concomitant use of buprenorphine and CYP3A4 inhibitors can increase the plasma concentration of buprenorphine, resulting in increased or prolonged opioid effects, particularly when an inhibitor is added after a stable dose of BUPRENEX is achieved.<br/>
<br/>After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, the buprenorphine plasma concentration will decrease <content stylecode="italics">[see CLINICAL PHARMACOLOGY: Pharmacokinetics]</content>, potentially resulting in decreased opioid efficacy or a withdrawal syndrome in patients who had developed physical dependence to buprenorphine.
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">If concomitant use is necessary, consider dosage reduction of BUPRENEX until stable drug effects are achieved. Monitor patients for respiratory depression and sedation at frequent intervals.<br/>
<br/>If a CYP3A4 inhibitor is discontinued, consider increasing the BUPRENEX dosage until stable drug effects are achieved.  Monitor for signs of opioid withdrawal.
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Examples:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g. ketoconazole), protease inhibitors (e.g., ritonavir)
</td>
</tr>
<tr>
<td align="left" colspan="2" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="bold">CYP3A4 Inducers</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">The concomitant use of buprenorphine  and CYP3A4 inducers can decrease the plasma concentration of buprenorphine <content stylecode="italics">[see CLINICAL PHARMACOLOGY: Pharmacokinetics]</content>
<content stylecode="italics">,</content> potentially resulting in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical dependence to buprenorphine.<br/>
<br/>After stopping a CYP3A4 inducer, as the effects of the inducer decline, the buprenorphine plasma concentration will increase <content stylecode="italics">[see CLINICAL PHARMACOLOGY: Pharmacokinetics]</content>
<content stylecode="italics">,</content> which could increase or prolong both therapeutic effects and adverse reactions and may cause serious respiratory depression.
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">If concomitant use is necessary, consider increasing the BUPRENEX dosage until stable drug effects are achieved. Monitor for signs of opioid withdrawal.<br/>
<br/>If a CYP3A4 inducer is discontinued, consider BUPRENEX dosage reduction and monitor for signs of respiratory depression.
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Examples:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Rifampin, carbamazepine, phenytoin
</td>
</tr>
<tr>
<td align="left" colspan="2" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="bold">Serotonergic Drugs</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome.
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment. Discontinue BUPRENEX if serotonin syndrome is suspected.
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Examples:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).
</td>
</tr>
<tr>
<td align="left" colspan="2" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="bold">Monoamine Oxidase Inhibitors (MAOIs)</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">MAOI interactions with opioids may manifest as serotonin syndrome opioid toxicity (e.g., respiratory depression, coma).
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">The use of BUPRENEX is not recommended for patients taking MAOIs or within 14 days of stopping such treatment.
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Examples:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">phenelzine, tranylcypromine, linezolid
</td>
</tr>
<tr>
<td align="left" colspan="2" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="bold">Mixed Agonist/Antagonist and Partial Agonist Opioid Analgesics</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">May reduce the analgesic effect of BUPRENEX and/or precipitate withdrawal symptoms.
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Avoid concomitant use.
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Examples:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">butorphanol, nalbuphine, pentazocine
</td>
</tr>
<tr>
<td align="left" colspan="2" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="bold">Muscle Relaxants</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Buprenorphine may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Monitor patients receiving muscle relaxants and BUPRENEX for signs of respiratory depression that may be greater than otherwise expected and decrease the dosage of BUPRENEX and/or the muscle relaxant as necessary.
</td>
</tr>
<tr>
<td align="left" colspan="2" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="bold">Diuretics</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone.
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Monitor patients for signs of diminished diuresis and/or effects on blood pressure and increase the dosage of the diuretic as needed.
</td>
</tr>
<tr>
<td align="left" colspan="2" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="bold">Anticholinergic Drugs</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">The concomitant use of anticholinergic drugs may increase the risk of urinary retention and/or severe constipation, which may lead to paralytic ileus.
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Monitor patients for signs of urinary retention or reduced gastric motility when BUPRENEX is used concomitantly with anticholinergic drugs.
</td>
</tr>
<tr>
<td align="left" colspan="2" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="bold">Antiretrovirals: Nucleoside reverse transcriptase inhibitors (NRTIs)</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Nucleoside reverse transcriptase inhibitors (NRTIs) do not appear to induce or inhibit the P450 enzyme pathway, thus no interactions with buprenorphine are expected.
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">None
</td>
</tr>
<tr>
<td align="left" colspan="2" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="bold">Antiretrovirals: Non-nucleoside reverse transcriptase inhibitors (NNRTIs)</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are metabolized principally by CYP3A4. Efavirenz, nevirapine, and etravirine are known CYP3A inducers, whereas delaviridine is a CYP3A inhibitor. Significant pharmacokinetic interactions between NNRTIs (e.g., efavirenz and delavirdine) and buprenorphine have been shown in clinical studies, but these pharmacokinetic interactions did not result in any significant pharmacodynamic effects.
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Patients who are on chronic BUPRENEX treatment should have their dose monitored if NNRTIs are added to their treatment regimen.
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Examples:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">efavirenz, nevirapine, etravirine, delavirdine
</td>
</tr>
<tr>
<td align="left" colspan="2" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="bold">Antiretrovirals: Protease inhibitors (PIs)</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Studies have shown some antiretroviral protease inhibitors (PIs) with CYP3A4 inhibitory activity (nelfinavir, lopinavir/ritonavir, ritonavir) have little effect on buprenorphine pharmacokinetic and no significant pharmacodynamic effects. Other PIs with CYP3A4 inhibitory activity (atazanavir and atazanavir/ritonavir) resulted in elevated levels of buprenorphine and norbuprenorphine, and patients in one study reported increased sedation. Symptoms of opioid excess have been found in post-marketing reports of patients receiving buprenorphine and atazanavir with and without ritonavir concomitantly.
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Monitor patients taking BUPRENEX and atazanavir with and without ritonavir, and dose reduction of BUPRENEX may be warranted.
</td>
</tr>
<tr>
<td align="right" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Examples:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">atazanavir, ritonavir
</td>
</tr>
</tbody>
</table>